BioCentury
ARTICLE | Company News

Management tracks

April 1, 2017 12:38 AM UTC

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty has joined Lightspeed Venture Partners, a Forty Seven investor, as a partner.

Drug delivery company Impax Laboratories Inc. (NASDAQ:IPXL) named Paul Bisaro president and CEO. He was executive chairman at Allergan plc (NYSE:AGN)...